166 related articles for article (PubMed ID: 30285776)
1. Cell adhesion-related gene somatic mutations are enriched in aggressive papillary thyroid microcarcinomas.
Song J; Wu S; Xia X; Wang Y; Fan Y; Yang Z
J Transl Med; 2018 Oct; 16(1):269. PubMed ID: 30285776
[TBL] [Abstract][Full Text] [Related]
2. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma.
Lee X; Gao M; Ji Y; Yu Y; Feng Y; Li Y; Zhang Y; Cheng W; Zhao W
Ann Surg Oncol; 2009 Feb; 16(2):240-5. PubMed ID: 19034577
[TBL] [Abstract][Full Text] [Related]
3. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma.
Lin KL; Wang OC; Zhang XH; Dai XX; Hu XQ; Qu JM
Ann Surg Oncol; 2010 Dec; 17(12):3294-300. PubMed ID: 20953721
[TBL] [Abstract][Full Text] [Related]
4. Morphological features predictive for BRAF(V600E) mutation in papillary thyroid microcarcinomas.
Nechifor-Boilă AC; Szász EA; Descotes F; Berger N; Zahan AE; Loghin A; Ceteraş DM; Borda A
Rom J Morphol Embryol; 2018; 59(3):747-753. PubMed ID: 30534813
[TBL] [Abstract][Full Text] [Related]
5. BRAF Status in Papillary Microcarcinomas of the Thyroid Gland: a Brief Review.
Ieni A; Vita R; Cardia R; Giuffré G; Benvenga S; Tuccari G
Curr Mol Med; 2019; 19(9):665-672. PubMed ID: 31625469
[TBL] [Abstract][Full Text] [Related]
6. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
[TBL] [Abstract][Full Text] [Related]
7. Whole-Exome Sequencing in Papillary Microcarcinoma: Potential Early Biomarkers of Lateral Lymph Node Metastasis.
Kim M; Kwon CH; Jang MH; Kim JM; Kim EH; Jeon YK; Kim SS; Choi KU; Kim IJ; Park M; Kim BH
Endocrinol Metab (Seoul); 2021 Oct; 36(5):1086-1094. PubMed ID: 34731936
[TBL] [Abstract][Full Text] [Related]
8. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
9. Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma.
Lu Z; Zhang Y; Feng D; Sheng J; Yang W; Liu B
Oncotarget; 2017 Jul; 8(28):45784-45792. PubMed ID: 28507274
[TBL] [Abstract][Full Text] [Related]
10. [Invasiveness of papillary thyroid microcarcinoma with BRAF mutation].
Yang X; Liang ZY; Meng C; Liang J; Yu Z; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):398-403. PubMed ID: 23987486
[TBL] [Abstract][Full Text] [Related]
11. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
[No Abstract] [Full Text] [Related]
12. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
[TBL] [Abstract][Full Text] [Related]
13. The Profile of Genetic Mutations in Papillary Thyroid Cancer Detected by Whole Exome Sequencing.
Fang Y; Ma X; Zeng J; Jin Y; Hu Y; Wang J; Liu R; Cao C
Cell Physiol Biochem; 2018; 50(1):169-178. PubMed ID: 30278442
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of expression of bcl-2 protein in papillary carcinomas and papillary microcarcinomas of the thyroid gland.
Mitselou A; Peschos D; Dallas P; Charalabopoulos K; Agnantis NJ; Vougiouklakis T
Exp Oncol; 2004 Dec; 26(4):282-6. PubMed ID: 15627060
[TBL] [Abstract][Full Text] [Related]
15. BRAF(V600E) Is Correlated with Recurrence of Papillary Thyroid Microcarcinoma: A Systematic Review, Multi-Institutional Primary Data Analysis, and Meta-Analysis.
Chen Y; Sadow PM; Suh H; Lee KE; Choi JY; Suh YJ; Wang TS; Lubitz CC
Thyroid; 2016 Feb; 26(2):248-55. PubMed ID: 26671072
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of whole-exome sequencing in fine-needle aspiration specimens of papillary thyroid microcarcinoma for the identification of novel gene mutations.
Ma L; Gao L; Hu Y; Li X; Liu C; Ji J; Shi X; Pan A; An Y; Luo N; Xia Y; Jiang Y
Clin Genet; 2024 May; 105(5):567-572. PubMed ID: 38326996
[TBL] [Abstract][Full Text] [Related]
17. Clinical features and therapeutic outcomes of patients with papillary thyroid microcarcinomas and larger tumors.
Zheng W; Wang X; Rui Z; Wang Y; Meng Z; Wang R
Nucl Med Commun; 2019 May; 40(5):477-483. PubMed ID: 30973839
[TBL] [Abstract][Full Text] [Related]
18. Identification of key genes associated with papillary thyroid microcarcinoma characteristics by integrating transcriptome sequencing and weighted gene co-expression network analysis.
Yang F; Lian M; Ma H; Feng L; Shen X; Chen J; Fang J
Gene; 2022 Feb; 811():146086. PubMed ID: 34856364
[TBL] [Abstract][Full Text] [Related]
19. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
[TBL] [Abstract][Full Text] [Related]
20. Tall cell variant of papillary thyroid microcarcinoma: clinicopathologic features with BRAF(V600E) mutational analysis.
Bernstein J; Virk RK; Hui P; Prasad A; Westra WH; Tallini G; Adeniran AJ; Udelsman R; Sasaki CT; Roman SA; Sosa JA; Prasad ML
Thyroid; 2013 Dec; 23(12):1525-31. PubMed ID: 23682579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]